Abstract P2-16-04: A phase 2 study of ridaforolimus (RIDA) and dalotuzumab (DALO) in estrogen receptor positive (ER+) breast cancer
José Baselga(Harvard University), HS Rugo(Texas Oncology), Ahmad Awada(Centre Hospitalier Interrégional Edith Cavell), Beverly Moy(Global Cancer Institute), JL Blum(Texas Oncology), Marianne Ewertz(Odense University Hospital), Tufia C. Haddad(Mayo Clinic), Peter Vuylsteke(Champalimaud Foundation), E. Im(Texas Oncology), Scot Ebbinghaus(Merck & Co., Inc., Rahway, NJ, USA (United States)), Javier Cortés(Villa Maria Hospital), Lamar Eaton(Merck & Co., Inc., Rahway, NJ, USA (United States)), Eva Ciruelos(Hospital Universitario 12 De Octubre), Serafín Morales(Hospital Universitari Arnau de Vilanova), K Prathiraja(Texas Oncology), AR Tan(Texas Oncology), KJ Ruddy(Texas Oncology), Christine K. Gause(Merck & Co., Inc., Rahway, NJ, USA (United States)), David Mauro(Merck & Co., Inc., Rahway, NJ, USA (United States))
Cited by 3
Related Papers
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
|New England Journal of Medicine|2013|3.4k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Breast cancer
|Nature Reviews Disease Primers|2019|2.9k